Patients with MET-amplification, EGFRm NSCLC after progression on EGFR-TKIs are eligible for the ongoing phase II SAVANNAH trial of the combination of osimertinib plus savolitinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.